Compare BioNTech SE - ADR (BNTX) vs Zscaler Inc (ZS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Zscaler Inc — how do they compare? BioNTech SE - ADR trades at $90.41 (market cap $22.86B), while Zscaler Inc trades at $153 (market cap $24.59B). The key difference: BioNTech SE - ADR and Zscaler Inc are close in size by market cap. Which is the better fit depends on your goals.
| BNTX | ZS | |
|---|---|---|
Market Cap | $22.86B | $24.59B |
Sector | Health | Technology |
52-Week High | $119.34 | $336.27 |
52-Week Low | $83.89 | $118.05 |
Enterprise Value | $6.53B | $22.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
Zscaler trades at $141.82, up 1.83% with bearish technical signals despite recent earnings beats. Revenue growth remains strong at $2.67B for 2025, though the company continues to report net losses. Analyst consensus is overwhelmingly bullish with a $192.64 price target, but multiple class action investigations and high valuation metrics create headwinds.
The stock faces near-term pressure from technical weakness and profitability challenges, but long-term prospects remain supported by cybersecurity demand and Zero Trust adoption. Key risks include ongoing litigation, AI infrastructure costs, and the transition to profitability amid slowing growth projections.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Zscaler Inc
Zscaler is a security-as-a-service firm that offers its customers cloud-delivered solutions for protecting user devices and data. The firm leverages its position in 150 colocation data centers to deliver traditionally appliance-based security functionality, such as firewalls and sandboxes, as a completely cloud-native platform. The firm focuses on large enterprise customers and offers two primary product suites: Zscaler Internet Access, which securely connects users to externally managed application and websites (such as Salesforce and Google), and Zscaler Private Access, which securely connects users to internally managed applications. Both product suites encompass a broad gamut of capabilities situated across the traditional security stack.
Read more on ZS →
